Borromeo MD, Savage TK, Kollipara RK, He M, Augustyn A, Osborne JK, Girard L, Minna JD, Gazdar AF, Cobb MH, Johnson JE (2016) ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. Cell Rep 16:1259-1272. https://doi.org/10.1016/j.celrep.2016.06.081

CAS  Article  PubMed  PubMed Central  Google Scholar 

Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG, Quaranta V, Sage J, Thomas RK, Vakoc CR, Gazdar AF (2019) Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer 19:289-297. https://doi.org/10.1038/s41568-019-0133-9

CAS  Article  PubMed  PubMed Central  Google Scholar 

Rekhtman N, Pietanza MC, Hellmann MD, Naidoo J, Arora A, Won H, Halpenny DF, Wang H, Tian SK, Litvak AM, Paik PK, Drilon AE, Socci N, Poirier JT, Shen R, Berger MF, Moreira AL, Travis WD, Rudin CM, Ladanyi M (2016) Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. Clin Cancer Res 22 :3618-3629. https://doi.org/10.1158/1078-0432.CCR-15-2946

CAS  Article  PubMed  PubMed Central  Google Scholar 

George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, Maas L, Müller C, Dahmen I, Delhomme TM, Ardin M, Leblay N, Byrnes G, Sun R, De Reynies A, McLeer-Florin A, Bosco G, Malchers F, Menon R, Altmüller J, Becker C, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soloway MG, Wilkerson MD, Cun Y, McKay JD, Moro-Sibilot D, Brambilla CG, Lantuejoul S, Lemaitre N, Soltermann A, Weder W, Tischler V, Brustugun OT, Lund-Iversen M, Helland Å, Solberg S, Ansén S, Wright G, Solomon B, Roz L, Pastorino U, Petersen I, Clement JH, Sänger J, Wolf J, Vingron M, Zander T, Perner S, Travis WD, Haas SA, Olivier M, Foll M, Büttner R, Hayes DN, Brambilla E, Fernandez-Cuesta L, Thomas RK (2018) Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun 9:1048. https://doi.org/10.1038/s41467-018-03099-x

CAS  Article  PubMed  PubMed Central  Google Scholar 

Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC (2018) Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer 124:807-815. https://doi.org/10.1002/cncr.31124

Article  PubMed  Google Scholar 

Lamarca A, Frizziero M, Barriuso J, McNamara MG, Hubner RA, Valle JW (2019) Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC). Clin Transl Oncol 21:950-953. https://doi.org/10.1007/s12094-018-1996-z

CAS  Article  PubMed  Google Scholar 

Abdel-Rahman O, Koski SL (2021) Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study. Neuroendocrinology. Oct 14. https://doi.org/10.1159/000520193

Uccella S, La Rosa S, Metovic J, Marchiori D, Scoazec JY, Volante M, Mete O, Papotti M (2021) Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites. Endocr Pathol 32:192-210. https://doi.org/10.1007/s12022-020-09660-z

Article  PubMed  Google Scholar 

Frizziero M, Durand A, Taboada RG, Zaninotto E, Luchini C, Chakrabarty B, Hervieu V, Claro LCL, Zhou C, Cingarlini S, Milella M, Walter T, Riechelmann RS, Lamarca A, Hubner RA, Mansoor W, Valle JW, McNamara MG (2021) Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant? Cancers (Basel) 13:4152. https://doi.org/10.3390/cancers13164152

CAS  Article  Google Scholar 

Priemer DS, Wang M, Zhang S, Lopez-Beltran A, Kouba E, Montironi R, Davidson DD, MacLennan GT, Wang L, Osunkoya AO, Deng Y, Emerson RE, Cheng L (2018) Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma. Eur Urol Focus 4:880-888. https://doi.org/10.1016/j.euf.2017.03.007

Article  PubMed  Google Scholar 

McNamara MG, Scoazec JY, Walter T (2020) Extrapulmonary poorly differentiated NECs, including molecular and immune aspects. Endocr Relat Cancer 27:R219-R238. https://doi.org/10.1530/ERC-19-0483

CAS  Article  PubMed  Google Scholar 

La Rosa S, Marando A, Gatti G, Rapa I, Volante M, Papotti M, Sessa F, Capella C (2013) Achaete-scute homolog 1 as a marker of poorly differentiated neuroendocrine carcinomas of different sites: a validation study using immunohistochemistry and quantitative real-time polymerase chain reaction on 335 cases. Hum Pathol 44:1391-1399. https://doi.org/10.1016/j.humpath.2012.11.013

CAS  Article  PubMed  Google Scholar 

González I, Lu HC, Sninsky J, Yang C, Bishnupuri K, Dieckgraefe B, Cao D, Chatterjee D (2019) Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts. Histopathology 75:568-577. https://doi.org/10.1111/his.13899

Article  PubMed  Google Scholar 

Roy M, Buehler DG, Zhang R, Schwalbe ML, Baus RM, Salamat MS, Lloyd RV, Rosenbaum JN (2019) Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites. Endocr Pathol 30:35-42. https://doi.org/10.1007/s12022-018-9559-y

CAS  Article  PubMed  Google Scholar 

Kim IE Jr, Amin A, Wang LJ, Cheng L, Perrino CM (2020) Insulinoma-associated Protein 1 (INSM1) Expression in Small Cell Neuroendocrine Carcinoma of the Urinary Tract. Appl Immunohistochem Mol Morphol 28:687-693. doi: https://doi.org/10.1097/PAI.0000000000000824

CAS  Article  PubMed  Google Scholar 

Jesinghaus M, Konukiewitz B, Keller G, Kloor M, Steiger K, Reiche M, Penzel R, Endris V, Arsenic R, Hermann G, Stenzinger A, Weichert W, Pfarr N, Klöppel G (2017) Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas. Mod Pathol 30:610-619. https://doi.org/10.1038/modpathol.2016.220

CAS  Article  PubMed  Google Scholar 

Sinha N, Gaston D, Manders D, Goudie M, Matsuoka M, Xie T, Huang WY (2018) Characterization of genome-wide copy number aberrations in colonic mixed adenoneuroendocrine carcinoma and neuroendocrine carcinoma reveals recurrent amplification of PTGER4 and MYC genes. Hum Pathol 73:16-25. https://doi.org/10.1016/j.humpath.2017.08.036

CAS  Article  PubMed  Google Scholar 

Moch O, Humphrey PA, Ulbright TM, Reuter VE, eds (2016) WHO classification of tumours of the urinary system and male genital organs. 4th ed. Lyon: IARC press.

Google Scholar 

Kurman RJ, Carcangiu ML, Herrington CS, Young RH, eds. (2014) WHO classification of tumours of female reproductive organs. 4th ed. Lyon: IARC press.

Google Scholar 

Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, eds (2015) WHO classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon: IARC press.

Google Scholar 

WHO classification of tumors Editorial Board, eds. (2019) Digestive system tumors. WHO classification of tumor, 5th ed. Lyon: IARC press.

Google Scholar 

Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, Ezzat S, de Herder WW, Klimstra DS, Papotti M, Asa SL (2022) Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol 33:115–154. https://doi.org/10.1007/s12022-022-09708-2.

Simbolo M, Mafficini A, Sikora KO, Fassan M, Barbi S, Corbo V, Mastracci L, Rusev B, Grillo F, Vicentini C, Ferrara R, Pilotto S, Davini F, Pelosi G, Lawlor RT, Chilosi M, Tortora G, Bria E, Fontanini G, Volante M, Scarpa A (2017) Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. J Pathol 241:488-500. https://doi.org/10.1002/path.4853

CAS  Article  PubMed  Google Scholar 

Simbolo M, Barbi S, Fassan M, Mafficini A, Ali G, Vicentini C, Sperandio N, Corbo V, Rusev B, Mastracci L, Grillo F, Pilotto S, Pelosi G, Pelliccioni S, Lawlor RT, Tortora G, Fontanini G, Volante M, Scarpa A, Bria E (2019) Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. J Thorac Oncol 14:1651-1661. https://doi.org/10.1016/j.jtho.2019.05.003

CAS  Article  PubMed  Google Scholar 

Pelosi G, Bianchi F, Dama E, Simbolo M, Mafficini A, Sonzogni A, Pilotto S, Harari S, Papotti M, Volante M, Fontanini G, Mastracci L, Albini A, Bria E, Calabrese F, Scarpa A (2018) Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm. Virchows Arch 472:567-577. https://doi.org/10.1007/s00428-018-2307-3

Article  PubMed  Google Scholar 

Miyashita N, Horie M, Suzuki HI, Yoshihara M, Djureinovic D, Persson J, Brunnström H, Lindskog C, Elfving H, Micke P, Saito A, Nagase T (2018) An Integrative Analysis of Transcriptome and Epigenome Features of ASCL1-Positive Lung Adenocarcinomas. J Thorac Oncol 13:1676-1691. https://doi.org/10.1016/j.jtho.2018.07.096

Article  PubMed  Google Scholar 

Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR; SCRX16-001 investigators (2017) Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol 18:42-51. https://doi.org/10.1016/S1470-2045(16)30565-4

Hermans BCM, Derks JL, Thunnissen E, van Suylen RJ, den Bakker MA, Groen HJM, Smit EF, Damhuis RA, van den Broek EC; PALGA-group, Ruland A, Speel EJM, Dingemans AMC (2019) DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile. Lung Cancer 138:102-108. https://doi.org/10.1016/j.lungcan.2019.10.010

CAS  Article  PubMed  Google Scholar 

Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, Isse K, Bishop E, Saunders LR, Balyimez A, Rashid S, Hu M, Stephenson AJ, Fergany AF, Lee BH, Haber GP, Dowlati A, Gilligan T, Ornstein MC, Rini BI, Abazeed ME, Mian OY, Grivas P (2019) Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clin Cancer Res 25:210-221. https://doi.org/10.1158/1078-0432.CCR-18-1278

CAS  Article  PubMed  Google Scholar 

Wael H, Yoshida R, Kudoh S, Hasegawa K, Niimori-Kita K, Ito T (2014) Notch1 signaling controls cell proliferation, apoptosis and differentiation in lung carcinoma. Lung Cancer 85:131-140. https://doi.org/10.1016/j.lungcan.2014.05.001

Article  PubMed  Google Scholar 

Sakakibara R, Kobayashi M, Takahashi N, Inamura K, Ninomiya H, Wakejima R, Kitazono S, Yanagitani N, Horiike A, Ichinose J, Matsuura Y, Nakao M, Mun M, Nishio M, Okumura S, Motoi N, Ito T, Miyazaki Y, Inase N, Ishikawa Y (2020) Insulinoma-associated Protein 1 (INSM1) Is a Better Marker for the Diagnosis and Prognosis Estimation of Small Cell Lung Carcinoma Than Neuroendocrine Phenotype Markers Such as Chromogranin A, Synaptophysin, and CD56. Am J Surg Pathol 44:757-764. https://doi.org/10.1097/PAS.0000000000001444

Article  PubMed  Google Scholar 

Chen C, Breslin MB, Lan MS (2018) Sonic hedgehog signaling pathway promotes INSM1 transcription factor in neuroendocrine lung cancer. Cell Signal 46:83-91. https://doi.org/10.1016/j.cellsig.2018.02.014

CAS  Article  PubMed  Google Scholar 

McColl K, Wildey G, Sakre N, Lipka MB, Behtaj M, Kresak A, Chen Y, Yang M, Velcheti V, Fu P, Dowlati A (2017) Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer. Oncotarget 8:73745–73756. https://doi.org/10.18632/oncotarget.20572

Baine MK, Hsieh MS, Lai WV, Egger JV, Jungbluth AA, Daneshbod Y, Beras A, Spencer R, Lopardo J, Bodd F, Montecalvo J, Sauter JL, Chang JC, Buonocore DJ, Travis WD, Sen T, Poirier JT, Rudin CM, Rekhtman N (2020) SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. J Thorac Oncol;15:1823–1835. https://doi.org/10.1016/j.jtho.2020.09.009